After weeks of speculation of how exactly another established alcohol company would dip into the cannabis space, on Wednesday (August 1) Molson Coors Brewing (NYSE:TAP; TSX:TPX) and The Hydropothecary Corporation (TSX:HEXO) confirmed a new partnership.

A joint venture will be developed between the two companies for the production of non-alcoholic beverages infused with cannabis. According to the announcement this new venture will be a standalone company with its own executive team and board of directors.


The split between the two companies’ controlling stake in the new venture is 57.5 percent for Molson and the remaining 42.5 percent for Hydropothecary, a company which recently graduated into the Toronto Stock Exchange (TSX).

The company is also in the process of changing its name to HEXO, the name of its cannabis brand.

Sebastien St-Louis, CEO of the cannabis producer said the two Quebec-based companies will begin working on the development of “responsible, high-quality cannabis-infused beverages.”

Canada is set to legalize the sale of recreational cannabis on October 17; however, edibles and other novel items like infused products will have to wait to enter the market.

Frederic Landtmeters, president and CEO of Molson Coors Canada said in a statement the company remains a beer business at the core but also enters the cannabis space through this new venture.

The entry of alcohol companies into the cannabis space

Last year the cannabis sector saw a pop industry wide following the announcement of an investment deal for Constellation Brands (NYSE:STZ), an alcohol producer behind Corona beer and Svedka Vodka into Canopy Growth (TSX:WEED; NYSE:CGC).

The deal represented an investment of approximately C$245 million into the leading cannabis company for a 9.9 percent interest. Since then Bruce Linton, CEO of Canopy, has indicated the two companies meet regularly and have a key interest in their own infused beverage products.

A variety of consumer studies have started to show the trend of alcohol consumption dropping in territories where cannabis becomes legal. A recent joint research study found over ten studied years, between 2006 and 2015, counties with legal medical cannabis caused a nearly 15 percent dip for alcohol sales per month.

Despite these predictions, the alcohol industry has embraced the potential of the cannabis space with the Wine & Spirits Wholesalers of America (WSWA) voicing their support for the legalization of adult-use cannabis in the US.

The association offered its support for the cause and even offered regulations it wishes to see in place for the legalization of the drug, like a minimum consumption and possession age of 21-years-old.

Investor takeaway

The share price for HEXO rose quickly on Wednesday’s trading session, reaching a price of C$4.94, a near 14 percent increase as of 1:40 p.m. EST.

Molson’s New York Stock Exchange (NYSE) stock also enjoyed a substantial increase on Wednesday as its share price rose 5.45 percent to reach a price tag of US$70.18.

The cannabis producer currently holds a favourable “Moderate Buy” rating on the analyst data aggregator site TipRanks, with the latest report issued today from Matt Bottomley at Canaccord Genuity.

Bottomley gave the company a “Buy” rating and stamped the company with a C$7.50 price target for one year. The average analyst price target for HEXO is C$7.13, equaling a 44.48 percent upside.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less